In the second quarter, revenue increased 39% year over year $362.9 million. There is room for improvement with more positive developments on the Elevidys front. Further, Sarepta has over 40 pipeline programs, including other investigational DMD medicines. In January, it started screening patients for a late-stage study for a potential therapy for Limb-girdle muscular dystrophy, another rare muscle disorder.